UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

Headache, 2020-09, Vol.60 (8), p.1734-1742

2020

Volltextzugriff (PDF)

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

The Lancet (British edition), 2008-08, Vol.372 (9639), p.646-655

2008

Volltextzugriff (PDF)

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant

Advances in therapy, 2021-10, Vol.38 (10), p.5209-5220

2021

Volltextzugriff (PDF)

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Gastroenterology (New York, N.Y. 1943), 2005-10, Vol.129 (4), p.1198-1209

2005

Volltextzugriff (PDF)

Identification of I50L as the Signature Atazanavir (ATV)-Resistance Mutation in Treatment-Naive HIV-1-Infected Patients Receiving ATV-Containing Regimens

The Journal of infectious diseases, 2004-05, Vol.189 (10), p.1802-1810

2004

Volltextzugriff (PDF)

Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Antiretroviral- Naive HIV-Infected Patients

Clinical infectious diseases, 2006-01, Vol.42 (2), p.273-280

2006

Volltextzugriff (PDF)

Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors

Antimicrobial Agents and Chemotherapy, 2003-04, Vol.47 (4), p.1324-1333

2003

Volltextzugriff (PDF)

Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis

Hepatology communications, 2018-09, Vol.2 (9), p.1123-1135

2018

Volltextzugriff (PDF)

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial

Headache, 2022-10, Vol.62 (9), p.1153-1163

2022

Volltextzugriff (PDF)

Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States

Journal of pain research, 2024-05, Vol.17, p.1805-1814

2024

Volltextzugriff (PDF)

A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine

Cephalalgia, 2024-04, Vol.44 (4), p.3331024241232944-3331024241232944

2024

Volltextzugriff (PDF)

Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials

Cephalalgia, 2023-02, Vol.43 (2), p.3331024221141686-3331024221141686

2023

Volltextzugriff (PDF)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine

Headache, 2021-06, Vol.61 (6), p.906-915

2021

Volltextzugriff (PDF)

Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis

Expert review of pharmacoeconomics & outcomes research, 2022-01, Vol.22 (1), p.155-166

2022

Volltextzugriff (PDF)

Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B

Hepatology (Baltimore, Md.), 2016-02, Vol.63 (2), p.377-387

2016

Volltextzugriff (PDF)

Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

Journal of pain research, 2024-07, Vol.17, p.2431-2441

2024

Volltextzugriff (PDF)

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

Journal of acquired immune deficiency syndromes (1999), 2003-01, Vol.32 (1), p.18

2003

Volltextzugriff (PDF)

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV

Journal of acquired immune deficiency syndromes (1999), 2004-08, Vol.36 (5), p.1011

2004

Volltextzugriff (PDF)

Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial

AIDS (London), 2003-06, Vol.17 (9), p.1339-1349

2003

Volltextzugriff (PDF)

Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States

Journal of pain research, 2024, Vol.17, p.1805-1814

2024

Volltextzugriff (PDF)

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients : 48 week efficacy and safety results of the CASTLE study. Commentary

The Lancet (British edition), 2008, Vol.372 (9639)

2008

Volltextzugriff (PDF)

Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary

Clinical infectious diseases, 2006, Vol.42 (2), p.273-282

2006

Volltextzugriff (PDF)

Atazanavir plus saquinavir once daily: favorable effects on lipid profiles in patients failing prior protease inhibitor therapy (trial AI424-009)

Journal of the American College of Cardiology, 2002-03, Vol.39, p.227-227

2002

Volltextzugriff (PDF)

Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 2004-07, Vol.3 (3), p.92-98

2004

Volltextzugriff (PDF)

Missing Data Methods in Hiv Clinical Trials: Regulatory Guidance and Alternative Approaches

Therapeutic innovation & regulatory science, 2001-10, Vol.35 (4), p.1363-1371

2001

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(35)
Science & Technology
(35)
Humans
(25)
Life Sciences
(14)
Sciences Du Vivant
(14)
Microbiology
(13)
Animals
(12)
Norovirus
(12)
Adult
(11)
Biological And Medical Sciences
(10)
Caliciviridae Infections - Virology
(10)
Male
(10)
Virology
(10)
Female
(9)
Infectious Diseases
(9)
Atazanavir Sulfate
(8)
Genotype
(8)
Microbiologie
(8)
Clinical Neurology
(7)
Gastroenteritis
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Identification of I50L as the Signature Atazanavir (ATV)-Resistance Mutation in Treatment-Naive HIV-1-Infected Patients Receiving ATV-Containing Regimens

Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Antiretroviral- Naive HIV-Infected Patients

Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors

Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial

Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States

A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine

Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine

Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis

Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B

Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV

Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial

Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients : 48 week efficacy and safety results of the CASTLE study. Commentary

Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary

Atazanavir plus saquinavir once daily: favorable effects on lipid profiles in patients failing prior protease inhibitor therapy (trial AI424-009)

Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials

Missing Data Methods in Hiv Clinical Trials: Regulatory Guidance and Alternative Approaches

Suchergebnisse filtern